US to Hit Drug Imports With 100% Tariff This Week

The Trump administration will impose a 100% tariff on imported patented drugs and pharmaceutical ingredients as soon as Thursday, leveraging a Cold War-era trade law to force price cuts and reshore production. The move, announced by the White House on April 2, invokes Section 232 of the Trade Expansion Act of 1962, which allows the president to impose tariffs on goods deemed critical to national security.

"Companies that do not have agreements and are not in negotiations with the administration will be subject to 100% tariffs," a source familiar with the plan told Bloomberg News. The administration has been in talks with major pharmaceutical companies to secure lower prices for the U.S. market and commitments to expand domestic manufacturing. The plans are not yet final and could include exemptions for certain medicines.

The announcement follows weeks of pressure on the pharmaceutical industry. Several major drugmakers have already moved to avoid the penalties. Pfizer and AstraZeneca secured multi-year tariff exemptions by striking pricing deals and committing to the new TrumpRx.gov drug discount platform. Meanwhile, Eli Lilly, Johnson & Johnson, and Merck have collectively pledged billions to expand their U.S. manufacturing footprint.

This tariff could cause major disruptions in the global pharmaceutical supply chain, potentially increasing costs for U.S. consumers and negatively impacting the stock prices of foreign pharmaceutical companies and U.S. firms that rely on imported ingredients. It may also lead to retaliatory actions from other nations, further escalating global trade disputes.

Pharma Scrambles to Avoid Penalties

The threat of a 100% tariff has sent shockwaves through the global pharmaceutical industry, which relies heavily on international supply chains for active pharmaceutical ingredients (APIs) and finished drugs. Companies without significant U.S. manufacturing operations are the most exposed. The administration's strategy appears to be a carrot-and-stick approach, offering tariff exemptions as a powerful incentive for companies to negotiate on price and invest in domestic production.

The creation of the TrumpRx.gov platform is a key component of this strategy, designed to bring transparency to drug pricing and offer consumers access to lower-cost medicines. Companies that participate in the platform and offer significant discounts are likely to be shielded from the new tariffs. The full list of companies subject to the tariffs has not yet been disclosed.

Broader Market Impact and Retaliation Risks

The use of the Section 232 provision, typically reserved for industries like steel and aluminum, marks a significant escalation in the administration's trade policy. The pharmaceutical sector is now in the crosshairs, with the government using national security as a justification for protecting the domestic drug supply. This action could set a precedent for other sectors and may invite legal challenges at the World Trade Organization.

The immediate market reaction was muted as the news broke after trading hours, but futures for healthcare-related indexes are expected to face pressure. The broader risk is one of retaliation. If other countries impose their own tariffs on U.S. goods, it could trigger a new front in the ongoing trade wars, creating further uncertainty for global markets.

This article is for informational purposes only and does not constitute investment advice.